Episode Details
Back to Episodes
Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo
Published 7 months, 3 weeks ago
Description
This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.